Figure S5.

Concentration-based HLA class I-peptide stabilization of predicted SARS-CoV-2 CD8⁺ T cell epitopes, related to Figure 3

Concentration-based HLA class I stabilization of 311 predicted SARS-CoV-2 CD8+ T cell epitopes (0.1-100 μM) across 18 TAP-deficient mono-allelic HLA class I-expressing cell lines. The y axis depicts the anti-HLA MFI normalized to the known immunodominant HIV CD8+ T cell epitope (red) for each HLA class I allele. SARS-CoV-2 epitopes with > 50% relative HLA class I stabilization to the HIV immunodominant epitope indicated in dark blue and those with < 50% relative stabilization are indicated in light blue. (B) HLA class I-peptide stabilization of TAP-deficient B^∗0702, B^∗1402, B^∗3901, B^∗8101 and Cw^∗0701 expressing cell lines following incubation with no peptide (gray), HLA-specific HIV immunodominant HIV epitope (10 μM, red) or Spike ML9 (10 μM, blue). (C) Comparison of normalized anti-HLA MFI for B^∗0702, B^∗1402, B^∗3901, B^∗8101 and Cw^∗0701 following incubation with immunodominant HIV epitope or ML9 peptide at range of concentrations (0.1-100 μM). Statistical comparisons were made using Mann-Whitney U test.